Three abstracts from SuperGen PIM kinase inhibitor program to be presented at AACR
 

SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced the acceptance of three abstracts from the SuperGen PIM kinase inhibitor program. Poster presentations by SuperGen and collaborators will occur on April 3 and 5, 2011 at the American Association for Cancer Research 102nd Annual Meeting in Orlando, Florida.

More...